What is HC Wainwright’s Forecast for Annexon Q2 Earnings?

Annexon, Inc. (NASDAQ:ANNX) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Annexon in a research note issued to investors on Tuesday, March 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.33) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.33) EPS and FY2029 earnings at $0.28 EPS.

Annexon (NASDAQ:ANNX) last posted its earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05).

Several other research firms have also commented on ANNX. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 target price on shares of Annexon in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Friday, November 15th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has an average rating of “Buy” and a consensus target price of $15.80.

Annexon Trading Down 2.9 %

Shares of ANNX stock opened at $2.68 on Thursday. The company has a market capitalization of $285.67 million, a price-to-earnings ratio of -2.55 and a beta of 1.14. Annexon has a twelve month low of $2.30 and a twelve month high of $8.40. The firm has a 50-day moving average price of $3.85 and a 200 day moving average price of $5.38.

Institutional Investors Weigh In On Annexon

Large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new stake in Annexon in the fourth quarter valued at approximately $59,000. CANADA LIFE ASSURANCE Co acquired a new stake in Annexon during the 4th quarter valued at approximately $77,000. E Fund Management Co. Ltd. raised its position in shares of Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company’s stock valued at $79,000 after purchasing an additional 4,086 shares in the last quarter. Forefront Analytics LLC grew its position in shares of Annexon by 56.8% during the fourth quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock worth $84,000 after buying an additional 5,950 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Annexon during the 4th quarter valued at $98,000.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.